Acute viral bronchiolitis in South Africa: Strategies for management and prevention.
Management of acute viral bronchiolitis is largely supportive. There is currently no proven effective therapy other than oxygen for hypoxic children. The evidence indicates that there is no routine benefit from inhaled, rapid short-acting bronchodilators, adrenaline or ipratropium bromide for children with acute viral bronchiolitis. Likewise, there is no demonstrated benefit from routine use of inhaled or oral corticosteroids, inhaled hypertonic saline nebulisation, montelukast or antibiotics. The last should be reserved for children with severe disease, when bacterial co-infection is suspected. Prevention of respiratory syncytial virus (RSV) disease remains a challenge. A specific RSV monoclonal antibody, palivizumab, administered as an intramuscular injection, is available for children at risk of severe bronchiolitis, including premature infants, young children with chronic lung disease, immunodeficiency, or haemodynamically significant congenital heart disease. Prophylaxis should be commenced at the start of the RSV season and given monthly during the season. The development of an RSV vaccine may offer a more effective alternative to prevent disease, for which the results of clinical trials are awaited. Education of parents or caregivers and healthcare workers about diagnostic and management strategies should include the following: bronchiolitis is caused by a virus; it is seasonal; it may start as an upper respiratory tract infection with low-grade fever; symptoms are cough and wheeze, often with fast breathing; antibiotics are generally not needed; and the condition is usually self limiting, although symptoms may occur for up to four weeks in some children.
H J
HJ
Zar
S A
SA
Madhi
D A
DA
White
R
R
Masekela
S
S
Risenga
H
H
Lewis
C
C
Feldman
B
B
Morrow
P
P
Jeena
D000208:Acute Disease; D000998:Antiviral Agents / Q000627:therapeutic use; D001990:Bronchiolitis, Viral / Q000517:prevention & control* / Q000628:therapy*; D017028:Caregivers / Q000193:education; D002648:Child; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature; D000069455:Palivizumab / Q000627:therapeutic use; D010290:Parents / Q000193:education; D010353:Patient Education as Topic; D018357:Respiratory Syncytial Virus Infections / Q000517:prevention & control; D012307:Risk Factors; D013019:South Africa; D014765:Viral Vaccines
D000998:Antiviral Agents; D014765:Viral Vaccines; D000069455:Palivizumab